FDA Approval: Novel Formulation for Treatment of Schizophrenia

September 11, 2024

Driving FDA Approvals with Precision and Speed

Discover how CRC’s expertise in clinical trial management supported the FDA approval of a novel formulation for schizophrenia treatment. Download the full case study to explore the challenges faced, proactive solutions implemented, and the strategic approach that delivered results on time and on budget.

October 10, 2025
CRC team members share what drives their commitment to advancing mental health clinical research and supporting sponsors developing innovative psychiatric therapies.
September 29, 2025
This World Alzheimer’s Month, CRC shares the personal stories that power our mission in Alzheimer’s research and inspire our work as a neuroscience-focused CRO.
neural network
September 10, 2025
Why do neuropsychiatric trials fail? Experts Dr. Steve Brannan and Dr. David Walling share strategies to protect investments in neuropsychiatric drug development.
Show More